Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
Berengere MolinaRoberto PadoanMaria Letizia UrbanPavel NovikovMarco CaminatiCamille TailléAntoine NéelLaurence BouilletPaolo FraticelliNicolas SchleinitzChristine ChristidesLaura MoiBertrand GodeauAnn KnightJan Walter SchroederSylvain Marchand-AdamHelder GilVincent CottinCécile-Audrey DurelElena GelainBoris LeraisMarc RuivardMatthieu GrohMaxime SamsonLuca MoroniJens ThielAnna KernderJan Willem Cohen TervaertGiulia CostanzoMarco FolciSonia RizzelloPascal CohenGiacomo EmmiBenjamin TerrierPublished in: Annals of the rheumatic diseases (2023)
These results suggest that dupilumab may be effective in treating patients with EGPA-related ENT manifestations. However, EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, suggesting that caution is required.